scispace - formally typeset
A

Antonio Passaro

Researcher at European Institute of Oncology

Publications -  125
Citations -  3138

Antonio Passaro is an academic researcher from European Institute of Oncology. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 19, co-authored 102 publications receiving 1776 citations. Previous affiliations of Antonio Passaro include Sapienza University of Rome & University of Milan.

Papers
More filters
Journal ArticleDOI

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.

TL;DR: With an ongoing global pandemic of COVID-19, the data suggest high mortality and low admission to intensive care in patients with thoracic cancer and whether mortality could be reduced with treatment in intensive care remains to be determined.
Journal ArticleDOI

Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus.

Giuseppe Curigliano, +68 more
- 01 Oct 2020 - 
TL;DR: An international consortium to develop expert consensus statements related to cancer management during the severe acute respiratory syndrome coronavirus 2-related disease (COVID-19) pandemic agreed on 28 consensus statements that can be used to overcome many of the clinical and technical areas of uncertainty.
Journal ArticleDOI

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

TL;DR: This study uncovers a coordinated signaling network centered on both STAT3 and Src-YAP signaling that limits targeted therapy response in lung cancer and identifies an unforeseen rational upfront polytherapy strategy to minimize residual disease and enhance clinical outcomes.
Journal ArticleDOI

Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies

TL;DR: In patients harboring EGFR mutations, the administration of EGFR TKIs is followed by a response rate of 70–80%, and a longer progression-free and overall survival than those obtained with standard chemotherapeutic regimens, this review is focused on the evidence for therapeutic strategies in bone and brain metastases due to lung cancer.